Catalyst Pharmaceuticals, Inc.
CPRX
株式のランク
#4177
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
株価
$31.49
最終同期: 2026-07-21
時価総額
$3.85B
変化（1日）
0.00%
変化（1年）
49.88%
国
US
取引 Catalyst Pharmaceuticals, Inc. (CPRX)
カテゴリー
Healthcare
Catalyst Pharmaceuticals, Inc.（CPRX）のP/E比率
October 2026 時点のP/E比率 TTM 17.49
Catalyst Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 17.49 です。2023 年末時点での P/E は 25.02 でした。
Catalyst Pharmaceuticals, Inc. の P/E 比率の履歴（2002 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 17.49 | 16.01% |
| 2024 | 15.08 | -39.71% |
| 2023 | 25.02 | 8.10% |
| 2022 | 23.14 | 30.56% |
| 2021 | 17.73 | 284.46% |
| 2020 | 4.61 | -61.93% |
| 2019 | 12.11 | -308.98% |
| 2018 | -5.80 | -68.19% |
| 2017 | -18.22 | 278.42% |
| 2016 | -4.82 | -50.82% |
| 2015 | -9.79 | -20.29% |
| 2014 | -12.28 | 68.45% |
| 2013 | -7.29 | 127.53% |
| 2012 | -3.20 | -26.92% |
| 2011 | -4.39 | -4.48% |
| 2010 | -4.59 | 250.29% |
| 2009 | -1.31 | -40.88% |
| 2008 | -2.22 | -78.76% |
| 2007 | -10.44 | -23.26% |
| 2006 | -13.60 | -35.11% |
| 2005 | -20.97 | -36.43% |
| 2004 | -32.98 | -20.60% |
| 2003 | -41.53 | -26.12% |
| 2002 | -56.22 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | 64.52% |
US
|
|
| -28.36 | -262.10% |
US
|
|
| -24.57 | -240.43% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 73.37% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。